Here’s Why ICON Plc. (ICLR) Gained +20.3% in Q3

3 weeks ago 8

Soumya Eswaran

Wed, December 17, 2025 astatine 7:53 AM CST 3 min read

GreensKeeper Asset Management, an concern absorption company, released its third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Value Fund has ended the 4th with a +4.0% gain, taking the YTD instrumentality to +0.2% nett of fees and expenses. The US dollar continued to airs a challenge, negatively impacting show by -3.7% truthful acold this year. The year’s marketplace rally was chiefly led by AI, crypto, and speculation. In addition, you tin cheque the fund’s apical 5 holdings to find its champion picks for 2025.

In its third-quarter 2025 capitalist letter, GreensKeeper Asset Management highlighted stocks specified arsenic ICON Public Limited Company (NASDAQ:ICLR). Headquartered successful Dublin, Ireland, ICON Public Limited Company (NASDAQ:ICLR) is simply a objective probe organization. The one-month instrumentality for ICON Public Limited Company (NASDAQ:ICLR) was 14.89%, and its shares mislaid 10.74% implicit the past 52 weeks. On December 16, 2025, ICON Public Limited Company (NASDAQ:ICLR) banal closed astatine $182.45 per share, with a marketplace capitalization of $14.19 billion.

GreensKeeper Asset Management stated the pursuing regarding ICON Public Limited Company (NASDAQ:ICLR) successful its 3rd 4th 2025 capitalist letter:

"Our 2nd apical contributor successful the 4th was ICON Public Limited Company (NASDAQ:ICLR) +20.3%. We archetypal purchased shares of ICLR earlier this twelvemonth arsenic tariff exposures, most-favoured-nation pricing, and looming patent cliffs led galore investors to fearfulness that pharmaceutical companies were astir to importantly trim their R&D investment. While the short-term manufacture dynamics were murky, we thought the market's absorption was excessively punitive. Admittedly, we did not person precocious visibility into ICLR’s 2025 earnings. Still, we believed the company’s agelong way grounds of execution and the benefits it brings to pharmaceutical R&D would alteration it to upwind a challenging period.